{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:54:11Z","timestamp":1773248051030,"version":"3.50.1"},"reference-count":20,"publisher":"SMW Supporting Association","issue":"3","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced hypothyroidism, myalgia, skin involvement, dyspnoea and diarrhoea. Laboratory tests revealed raised inflammatory markers, hypercreatinekinasemia and anti-MDA5 autoantibodies. Electroneuromyography and pathognomonic signs on physical examination confirmed the diagnosis of pauci-myopathic dermatomyositis. Pembrolizumab was discontinued and immunosuppressive therapy led to rapid and progressive improvement, with complete remission of dermatomyositis. This case report widens the spectrum of systemic immune-related adverse events associated with pembrolizumab.<\/jats:p>","DOI":"10.57187\/s.3513","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T22:29:40Z","timestamp":1709591380000},"page":"3513","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report"],"prefix":"10.57187","volume":"154","author":[{"given":"Antonino Marcello","family":"Pilia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-0392","authenticated-orcid":false,"given":"Lorenzo","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Guidolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-7839","authenticated-orcid":false,"given":"Francesca","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-5089","authenticated-orcid":false,"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Liotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"86484","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; c2017-2023 [cited 2023 November 04]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"86485","doi-asserted-by":"crossref","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan;378(2):158\u201368. 10.1056\/NEJMra1703481","DOI":"10.1056\/NEJMra1703481"},{"key":"86486","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al.; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov;375(19):1823\u201333. 10.1056\/NEJMoa1606774","DOI":"10.1056\/NEJMoa1606774"},{"key":"86487","doi-asserted-by":"crossref","unstructured":"Takatsuki K, Yanagihara T, Egashira A, Ogo N, Yoshizawa S, Sunami S, et al. A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin. Am J Case Rep. 2021 Apr;22:e930286. 10.12659\/AJCR.930286","DOI":"10.12659\/AJCR.930286"},{"key":"86488","doi-asserted-by":"crossref","unstructured":"Kartolo A, Towheed T, Mates M. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis. Immunotherapy. 2021 Apr;13(6):477\u201381. 10.2217\/imt-2020-0309","DOI":"10.2217\/imt-2020-0309"},{"key":"86489","unstructured":"European Medicines Agency. Keytruda Product Information. Annex I. Summary of product characteristics. [cited 2023 November 04] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"86490","unstructured":"European database of suspected adverse drug reactions reports [cited 2023 November 04] Available from: https:\/\/www.adrreports.eu\/en\/index.html"},{"key":"86491","doi-asserted-by":"crossref","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021 Oct;12:773352. 10.3389\/fimmu.2021.773352","DOI":"10.3389\/fimmu.2021.773352"},{"key":"86492","doi-asserted-by":"crossref","unstructured":"Parronchi P, Radice A, Palterer B, Liotta F, Scaletti C. MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations. Clin Mol Allergy. 2015 Nov;13(1):22. 10.1186\/s12948-015-0031-y","DOI":"10.1186\/s12948-015-0031-y"},{"key":"86493","doi-asserted-by":"crossref","unstructured":"So H, So J, Lam TT, Wong VT, Ho R, Li WL, et al. Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis. Front Med (Lausanne). 2022 Feb;9:837024. 10.3389\/fmed.2022.837024","DOI":"10.3389\/fmed.2022.837024"},{"key":"86494","doi-asserted-by":"crossref","unstructured":"Zhang SH, Zhao Y, Xie QB, Jiang Y, Wu YK, Yan B. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol. 2019 May;180(5):1090\u20138. 10.1111\/bjd.16917","DOI":"10.1111\/bjd.16917"},{"key":"86495","doi-asserted-by":"crossref","unstructured":"Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022 Dec;42(12):2267\u201376. 10.1007\/s00296-022-05176-3","DOI":"10.1007\/s00296-022-05176-3"},{"key":"86496","doi-asserted-by":"crossref","unstructured":"Wu M, Karim M, Ashinoff R. COVID-19 vaccine-associated dermatomyositis. JAAD Case Rep. 2022 May;23:58\u201360. 10.1016\/j.jdcr.2022.02.023","DOI":"10.1016\/j.jdcr.2022.02.023"},{"key":"86497","doi-asserted-by":"crossref","unstructured":"Ganatra K, Aggarwal R, Gupta L. Mechanic\u2019s Hand Heralding Relapse in an Indian Adolescent with Anti-MDA5 Positive Juvenile Dermatomyositis. Mediterr J Rheumatol. 2022 Jun;33(2):268\u201370. 10.31138\/mjr.33.2.268","DOI":"10.31138\/mjr.33.2.268"},{"key":"86498","doi-asserted-by":"crossref","unstructured":"Kawakami N, Eda H, Nishiura M, Chaya A, Saito F, Namkoong H. A decade of Gottron\u2019s papules, inverse Gottron\u2019s papules and mechanic\u2019s hand in anti-MDA5-associated interstitial lung disease with clinically amyopathic dermatomyositis. Oxf Med Case Rep. 2020 Jun;2020(6):omaa039. 10.1093\/omcr\/omaa039","DOI":"10.1093\/omcr\/omaa039"},{"key":"86499","doi-asserted-by":"crossref","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020 Mar;72(3):488\u201398. 10.1002\/art.41105","DOI":"10.1002\/art.41105"},{"key":"86500","doi-asserted-by":"crossref","unstructured":"Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol. 2021 Apr;60(2):293\u2013304. 10.1007\/s12016-020-08822-5","DOI":"10.1007\/s12016-020-08822-5"},{"key":"86501","doi-asserted-by":"crossref","unstructured":"Wang LM, Yang QH, Zhang L, Liu SY, Zhang PP, Zhang X, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology (Oxford). 2022 Aug;61(9):3704\u201310. 10.1093\/rheumatology\/keab928","DOI":"10.1093\/rheumatology\/keab928"},{"key":"86502","doi-asserted-by":"crossref","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jul;381(3):291\u20133. 10.1056\/NEJMc1900045","DOI":"10.1056\/NEJMc1900045"},{"key":"86503","doi-asserted-by":"crossref","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019 Sep;16(9):563\u201380. 10.1038\/s41571-019-0218-0","DOI":"10.1038\/s41571-019-0218-0"}],"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3513\/5863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3513\/5864","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/3513\/5863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T22:29:48Z","timestamp":1709591388000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/3513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.57187\/s.3513","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}